Cited by 2,098SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

SARS-CoV-2 vaccines in development

Open access

Krammer, Florian·2020·Nature

Open this paper in CoChat — free account

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.

Integrity signals

Registry

Crossref · 10.1038/s41586-020-2798-3

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Origin and evolution of pathogenic coronaviruses
Cui, J., Li, F., & Shi, Z. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0118-9 · Cited by 5,729
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Self-citation
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2
Shi, J., Wen, Z., Zhong, G., Yang, H., Wang, C., Huang, B., Liu, R., He, X., Shuai, L., Sun, Z., et al. (2020) · Science · doi:10.1126/science.abb7015 · Cited by 1,952

Show all 101 references

Research works printed but not linked: 1

The National Academies of Sciences, Engineering and Medicine. Discussion Draft of the Preliminary Framework for Equitable Allocation of COVID-19 Vaccine (The National Academies Press, 2020).

Sorted by citations

Items 401–500 of 1,004

COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control
Buchy, P., Buisson, Y., Cintra, O. A. L., Dwyer, D. E., Nissen, M. D., de Lejarazu, R. O., & Petersen, E. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.045 · Cited by 46
Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii
Berndt, A., Smalley, T. N., Ren, B., Simkovsky, R., Badary, A., Sproles, A. E., Fields, F. J., Torres-Tiji, Y., Heredia, V., & Mayfield, S. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257089 · Cited by 50
Virus-specific editing identification approach reveals the landscape of A-to-I editing and its impacts on SARS-CoV-2 characteristics and evolution
Song, Y., He, X., Yang, W., Wu, Y., Cui, J., Tang, T., & Zhang, R. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac120 · Cited by 45
Correlation of gut microbiota and metabolic functions with the antibody response to the BBIBP-CorV vaccine
Tang, B., Tang, L., He, W., Jiang, X., Hu, C.-J., Li, Y., Zhang, Y., Pang, K., Lei, Y., Li, S., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100752 · Cited by 42
A single BNT162b2 mRNA dose elicits antibodies with Fc-mediated effector functions and boost pre-existing humoral and T cell responsesPreprint
Tauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.18.435972 · Cited by 41
COVID-19 vaccine race: watch your step for cancer patients
Fanciullino, R., Ciccolini, J., & Milano, G. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01219-3 · Cited by 40
Secretory IgA and T cells targeting SARS-CoV-2 spike protein are transferred to the breastmilk upon mRNA vaccination
Gonçalves, J., Juliano, A. M., Charepe, N., Alenquer, M., Athayde, D., Ferreira, F., Archer, M., Amorim, M. J., Serrano, F., & Soares, H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100468 · Cited by 41
Protein-based nanocages for vaccine development
Kim, S. A., Lee, Y., Ko, Y., Kim, S., Kim, G. B., Lee, N. K., Ahn, W., Kim, N., Nam, G., Lee, E. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.022 · Cited by 41
Potential Biomedical Limitations of Graphene Nanomaterials
Ban, G., Hou, Y., Shen, Z., Jia, J., Chai, L., & Ma, C. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s402954 · Cited by 40
High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
Tan, T. J. C., Mou, Z., Lei, R., Ouyang, W. O., Yuan, M., Song, G., Andrabi, R., Wilson, I. A., Kieffer, C., Dai, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37786-1 · Cited by 40
Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2
Liang, Y., Zhang, J., Yuan, R. Y., Wang, M. Y., He, P., Su, J. G., Han, Z. B., Jin, Y. Q., Hou, J. W., Zhang, H., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00383-5 · Cited by 42
COVID-19 vaccine dose sparing: strategies to improve vaccine equity and pandemic preparedness
Roozen, G. V. T., Roukens, A. H. E., & Roestenberg, M. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00075-4 · Cited by 40
Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?
Misra, A., & Theel, E. S. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00482-21 · Cited by 43
Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals
Ye, Z.-W., Ong, C. P., Tang, K., Fan, Y., Luo, C., Zhou, R., Luo, P., Cheng, Y., Gray, V. S., Wang, P., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00855-4 · Cited by 43
The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBDPreprint
Amanat, F., Thapa, M., Lei, T., Ahmed, S. M. S., Adelsberg, D. C., Carreño, J. M., Strohmeier, S., Schmitz, A. J., Zafar, S., Zhou, J. Q., et al. (2021) · medRxiv · doi:10.1101/2021.03.07.21253098 · Cited by 41
Self-citation
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
Soh, S. M., Kim, Y., Kim, C., Jang, U. S., & Lee, H.-R. (2021) · The Journal of Microbiology · doi:10.1007/s12275-021-1348-5 · Cited by 39
COVID-19 Vaccines: Current and Future Perspectives
Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M. E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10040608 · Cited by 42
Future perspectives on swine viral vaccines: where are we headed?
Opriessnig, T., Mattei, A. A., Karuppannan, A. K., & Halbur, P. G. (2021) · Porcine Health Management · doi:10.1186/s40813-020-00179-7 · Cited by 39
SARS-CoV-2 Disease through Viral Genomic and Receptor Implications: An Overview of Diagnostic and Immunology Breakthroughs
Inchingolo, A. D., Inchingolo, A. M., Bordea, I. R., Malcangi, G., Xhajanka, E., Scarano, A., Lorusso, F., Farronato, M., Tartaglia, G. M., Isacco, C. G., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040793 · Cited by 43
A novel pseudovirus‐based mouse model of SARS-CoV-2 infection to test COVID-19 interventions
Tseng, S.-H., Lam, B. K., Kung, Y. J., Lin, J. W., Liu, L., Tsai, Y. C., Ferrall, L., Roden, R. B. S., Wu, T. ‐., & Hung, C. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00729-3 · Cited by 38
Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity
Rand, U., Kupke, S. Y., Shkarlet, H., Hein, M. D., Hirsch, T., Marichal‐Gallardo, P., Čičin‐Šain, L., Reichl, U., & Bruder, D. (2021) · Cells · doi:10.3390/cells10071756 · Cited by 42
SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
Law, J. L., Logan, M. R., Joyce, M., Landi, A., Hockman, D. J., Crawford, K., Johnson, J., LaChance, G., Saffran, H. A., Shields, J. A., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.081 · Cited by 41
Vaccine Refusal in the Czech Republic Is Associated with Being Spiritual but Not Religiously Affiliated
Košárková, A., Maliňáková, K., van Dijk, J. P., & Tavel, P. (2021) · Vaccines · doi:10.3390/vaccines9101157 · Cited by 40
Screening HLA-A-restricted T cell epitopes of SARS-CoV-2 and the induction of CD8+ T cell responses in HLA-A transgenic mice
Jin, X., Ding, Y., Sun, S., Wang, X., Zhou, Z., Liu, X. K., Li, M., Chen, X., Shen, A., Wu, Y., et al. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00784-8 · Cited by 39
A second functional furin site in the SARS-CoV-2 spike protein
Zhang, Y., Zhang, L., Wu, J., Yu, Y., Liu, S., Li, T., Li, Q., Ding, R., Wang, H., Nie, J., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.2014284 · Cited by 42
Intranasal administration of a virus like particles‐based vaccine induces neutralizing antibodies against SARS‐CoV‐2 and variants of concern
Rothen, D. A., Krenger, P. S., Nonic, A., Baļķe, I., Vogt, A. S., Chang, X., Manenti, A., Vedovi, F., Resēviča, G., Walton, S. M., et al. (2022) · Allergy · doi:10.1111/all.15311 · Cited by 39
COVID‐19 and novel mRNA vaccines in pregnancy: an updated literature review
Joubert, E., Kekeh, A., & Amin, C. (2021) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.16973 · Cited by 36
Postbiotics as potential promising tools for SARS-CoV-2 disease adjuvant therapy
Khani, N., Soleimani, R. A., Noorkhajavi, G., Soleimani, A. A., Abbasi, A., & Rad, A. H. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15457 · Cited by 39
Automating pandemic mitigation
Magid, E., Zakiev, A., Tsoy, T., Lavrenov, R., & Rizvanov, A. A. (2021) · Advanced Robotics · doi:10.1080/01691864.2021.1905059 · Cited by 40
Immunization with RBD-P2 and N protects against SARS-CoV-2 in nonhuman primates
Hong, S., Oh, H., Park, Y. W., Kwak, H. W., Oh, E. Y., Park, H., Kang, K. W., Kim, G., Koo, B., Hwang, E.-H., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7156 · Cited by 38
A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2
Nathan, R. V., Shawa, I., de la Torre, I., Pustizzi, J., Haustrup, N., Patel, D. R., & Huhn, G. D. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00515-6 · Cited by 40
A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine
Zhu, J., Jain, S., Sha, J., Batra, H., Ananthaswamy, N., Kilgore, P. B., Hendrix, E. K., Hosakote, Y. M., Wu, X., Olano, J. P., et al. (2022) · mBio · doi:10.1128/mbio.01822-22 · Cited by 39
Viral vector and nucleic acid vaccines against COVID-19: A narrative review
Khoshnood, S., Ghanavati, R., Shirani, M., Ghahramanpour, H., Sholeh, M., Shariati, A., Sadeghifard, N., & Heidary, M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.984536 · Cited by 35
CRISPR techniques and potential for the detection and discrimination of SARS-CoV-2 variants of concern
Xiao, H., Hu, J., Huang, C., Feng, W., Liu, Y., Kumblathan, T., Tao, J., Xu, J., Le, X. C., & Zhang, H. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117000 · Cited by 39
Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes
Fu, D. B., Zhang, G., Wang, Y., Zhang, Z., Hu, H., Shěn, S., Wu, J., Li, B., Li, X., Fang, Y., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001209 · Cited by 38
Immune Response to SARS-CoV-2 Vaccines
Bellamkonda, N., Lambe, U. P., Sawant, S. A., Nandi, S. S., Chakraborty, C., & Shukla, D. (2022) · Biomedicines · doi:10.3390/biomedicines10071464 · Cited by 37
COVID-19 and vaccination: myths vs science
Chavda, V. P., Chen, Y., Dave, J. B., Chen, Z., Chauhan, S. C., Yallapu, M. M., Uversky, V. N., Bezbaruah, R., Patel, S., & Apostolopoulos, V. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2114900 · Cited by 37
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
Canedo-Marroquín, G., Saavedra, F., Andrade, C. A., Berríos-Rojas, R. V., Rodríguez‐Guilarte, L., Opazo, M. C., Riedel, C. A., & Kalergis, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569760 · Cited by 40
Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients
Zhu, L., Xu, X. P., Zhu, B., Guo, X., Xu, K., Song, C., Fu, J., Yu, H., Kong, X., Peng, J., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00590-21 · Cited by 38
Development of an Inactivated Vaccine against SARS CoV-2
Pavel, S. T. I., Yetişkin, H., Uygut, M. A., Aslan, A. F., Aydın, G., İnan, Ö., Kaplan, B., & Özdarendeli, A. (2021) · Vaccines · doi:10.3390/vaccines9111266 · Cited by 40
Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants
Sun, C., Kang, Y., Liu, Y.-T., Kong, X., Xu, H.-Q., Xiong, D., Xie, C., Liu, Y., Peng, S., Feng, G., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00910-6 · Cited by 38
Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice
González‐Domínguez, I., Martínez, J. L., Slamanig, S., Lemus, N., Liu, Y., Lai, T. Y., Carreño, J. M., Singh, G., Singh, G., Schotsaert, M., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01538-22 · Cited by 37
Self-citation
Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview
Gholizadeh, O., Yasamineh, S., Amini, P., Afkhami, H., Delarampour, A., Akbarzadeh, S., Matloub, R. K., Zahedi, M., Hosseini, P., Hajiesmaeili, M., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01935-7 · Cited by 38
A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection
Miller, A., Leach, A., Thomas, J. C., McAndrew, C., Bentley, E. M., Mattiuzzo, G., John, L., Mirazimi, A., Harris, G., Gamage, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-89957-z · Cited by 34
Rational structural design of aromatic Azo photoactive small molecules for biomedical applications
Ding, J., Huang, Z. H., Zhang, D., Qu, Y., Zhang, S., Zhang, C., Fang, B., Li, L., & Huang, W. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00334b · Cited by 38
Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes
Grainger, R., Machado, P., & Robinson, P. C. (2020) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2020.101657 · Cited by 39
SARS‐CoV‐2 candidate vaccines ‐ composition, mechanisms of action and stages of clinical development
Rodríguez‐Coira, J., & Sokołowska, M. (2020) · Allergy · doi:10.1111/all.14714 · Cited by 37
The challenge of avidity determination in SARS‐CoV‐2 serology
Bauer, G., Struck, F., Schreiner, P. A., Staschik, E., Soutschek, E., & Motz, M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26863 · Cited by 39
An ultrapotent pan-β-coronavirus lineage B (β-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope
Liu, Z., Xu, W., Chen, Z., Fu, W., Zhan, W., Gao, Y., Zhou, J., Zhou, Y., Wu, J., Wang, Q., et al. (2021) · Protein & Cell · doi:10.1007/s13238-021-00871-6 · Cited by 38
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants
Pishesha, N., Harmand, T. J., Rothlauf, P. W., Praest, P., Alexander, R., van den Doel, R., Liebeskind, M. J., Vakaki, M. A., McCaul, N., Wijne, C., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116147118 · Cited by 35
Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination
Huang, L., Li, Y., Luo, C., Chen, Y., Touil, N., Annaz, H. E., Zeng, S., Dang, T., Liang, J., Hu, W., et al. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113868 · Cited by 36
Vaccine‐induced binding and neutralizing antibodies against Omicron 6 months after a homologous BNT162b2 booster
Favresse, J., Gillot, C., Bayart, J., David, C., Simon, G., Wauthier, L., Closset, M., Dogné, J., & Douxfils, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28164 · Cited by 33
Mucosal TLR2-activating protein-based vaccination induces potent pulmonary immunity and protection against SARS-CoV-2 in mice
Ashhurst, A. S., Johansen, M. D., Maxwell, J. W. C., Stockdale, S., Ashley, C. L., Aggarwal, A., Siddiquee, R., Miemczyk, S., Nguyen, D. H., Mackay, J. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34297-3 · Cited by 39
Structural and biochemical characteristics of mRNA nanoparticles determine anti–SARS-CoV-2 humoral and cellular immune responses
Shi, Y., Huang, J., Liu, Y., Liu, J., Guo, X., Li, J., Gong, L., Zhou, X., Cheng, G., Qiu, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo1827 · Cited by 36
Recent advances in respiratory immunization: A focus on COVID-19 vaccines
He, X., Chen, X., Wang, H., Du, G., & Sun, X. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.011 · Cited by 37
SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodiesPreprint
Moyo-Gwete, T., Madzivhandila, M., Makhado, Z., Ayres, F., Mhlanga, D., Oosthuysen, B., Lambson, B., Kgagudi, P., Tegally, H., Iranzadeh, A., et al. (2021) · bioRxiv · doi:10.1101/2021.03.06.434193 · Cited by 134
DNA vaccination induced protective immunity against SARS CoV-2 infection in hamsterss
Chai, K. M., Tzeng, T.-T., Shen, K., Liao, H., Lin, J.-J., Chen, M., Yu, G., Dou, H.-Y., Liao, C., Chen, H., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009374 · Cited by 36
Pharmacovigilance in Vaccines: Importance, Main Aspects, Perspectives, and Challenges—A Narrative Review
Hodel, K. V. S., Fiuza, B. S. D., Conceição, R. S., Aleluia, A. C. M., Pitanga, T. N., Fonseca, L. M. D. S., Valente, C. O., Rezende, C. S. M. E., & Machado, B. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17060807 · Cited by 38
Graphene Metasurface Based Biosensor for COVID-19 Detection in the Terahertz Regime with Machine Learning Optimization using K-Nearest Neighbours Regression
Wekalao, J., Mandela, N., Selvam, A. K., Venugopal, S., Ravi, D., Pandian, P., Babu, A. J., Leon, M. L., & Rashed, A. N. Z. (2024) · Plasmonics · doi:10.1007/s11468-024-02686-7 · Cited by 35
Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
Yang, Y., Shi, W., Abiona, O. M., Nazzari, A. F., Olia, A. S., Ou, L., Phung, E., Stephens, T., Tsybovsky, Y., Verardi, R., et al. (2021) · Vaccines · doi:10.3390/vaccines9020073 · Cited by 36
Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase
Kasprzyk, R., Śpiewla, T., Śmietański, M., Golojuch, S., Vangeel, L., Jonghe, S. D., Jochmans, D., Neyts, J. H., Kowalska, J., & Jemielity, J. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105142 · Cited by 39
The mutational landscape of SARS-CoV-2 variants diversifies T cell targets in an HLA-supertype-dependent manner
Hamelin, D. J., Fournelle, D., Grenier, J., Schockaert, J., Kovalchik, K. A., Kubiniok, P., Mostefai, F., Duquette, J. D., Saab, F., Sirois, I., et al. (2021) · Cell Systems · doi:10.1016/j.cels.2021.09.013 · Cited by 35
Determination of lipid content and stability in lipid nanoparticles using ultra high‐performance liquid chromatography in combination with a Corona Charged Aerosol Detector
Kinsey, C., Lu, T., Deiss, A., Vuolo, K., Klein, L. J., Rustandi, R. R., & Loughney, J. W. (2021) · Electrophoresis · doi:10.1002/elps.202100244 · Cited by 35
Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody
Torres, J. L., Ozorowski, G., Andreano, E., Liu, H., Copps, J., Piccini, G., Donnici, L., Conti, M., Planchais, C., Planas, D., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2120976119 · Cited by 33
Retinol Depletion in COVID-19
Sarohan, A. R., Akelma, H., Araç, E., Aslan, Ö., & Çen, O. (2022) · Clinical Nutrition Open Science · doi:10.1016/j.nutos.2022.05.007 · Cited by 34
Nanovaccines against Viral Infectious Diseases
Heng, W. T., Yew, J. S., & Poh, C. L. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122554 · Cited by 37
Corona's new coat: SARS-CoV-2 in Danish minks and implications for travel medicine
Larsen, C. S., & Paludan, S. R. (2020) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2020.101922 · Cited by 35
Nervous and Muscular Adverse Events after COVID-19 Vaccination: A Systematic Review and Meta-Analysis of Clinical Trials
Chen, J., Cai, Y., Chen, Y., Williams, A. P., Gao, Y., & Zeng, J. (2021) · Vaccines · doi:10.3390/vaccines9080939 · Cited by 35
Comparison of two commercial surrogate ELISAs to detect a neutralising antibody response to SARS-CoV-2
Müller, K., Girl, P., von Buttlar, H., Dobler, G., & Wölfel, R. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114122 · Cited by 33
Can drug repurposing strategies be the solution to the COVID-19 crisis?
Bellera, C., Llanos, M., Gantner, M., Rodríguez, S., Gavernet, L., Comini, M., & Talevi, A. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1863943 · Cited by 22
A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response
Lainšček, D., Fink, T., Forstnerič, V., Hafner‐Bratkovič, I., Orehek, S., Strmšek, Ž., Manček‐Keber, M., Pečan, P., Esih, H., Malenšek, Š., et al. (2021) · Vaccines · doi:10.3390/vaccines9050431 · Cited by 35
The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
Vaquero, S. T., de Campos‐Mata, L., Ramada, J. M., Díaz, P., Navarro‐Barriuso, J., Ribas‐Llauradó, C., Melero, N. R., Carolis, C., Cerutti, A., Gimeno, R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737083 · Cited by 34
An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats
Langereis, M. A., Albulescu, I. C., Stammen‐Vogelzangs, J., Lambregts, M., Stachura, K., Miller, S., Bosco‐Lauth, A. M., Hartwig, A. E., Porter, S. M., Allen, M. H., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00390-9 · Cited by 32
A two-adjuvant multiantigen candidate vaccine induces superior protective immune responses against SARS-CoV-2 challenge
Jiang, W., Shi, L., Cai, L., Wang, X., Li, J., Li, H., Liang, J., Gu, Q., Ji, G., Li, J., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110112 · Cited by 33
The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice
Bayarri‐Olmos, R., Johnsen, L. B., Idorn, M., Reinert, L. S., Rosbjerg, A., Vang, S., Hansen, C. B., Helgstrand, C., Bjelke, J. R., Bak-Thomsen, T., et al. (2021) · eLife · doi:10.7554/elife.70002 · Cited by 34
Phosphate-mediated coanchoring of RBD immunogens and molecular adjuvants to alum potentiates humoral immunity against SARS-CoV-2
Rodrigues, K. A., Rodriguez‐Aponte, S. A., Dalvie, N. C., Lee, J. H., Abraham, W. D., Carnathan, D. G., Jimenez, L. E., Ngo, J. T., Chang, J. Y. H., Zhang, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj6538 · Cited by 36
Engineered disulfide reveals structural dynamics of locked SARS-CoV-2 spike
Qu, K., Chen, Q., Ciazynska, K. A., Liu, B., Zhang, X., Wang, J., He, Y., Guan, J., He, J., Liu, T., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010583 · Cited by 33
Inactivation of SARS-CoV-2 and photocatalytic degradation by TiO2 photocatalyst coatings
Lu, Y., Guan, S., Hao, L., Yoshida, H. K., Nakada, S., Takisawa, T., & Itoi, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-20459-2 · Cited by 34
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 Vaccine
Lam, J. H., Shivhare, D., Chia, T. W., Chew, S. L., Sinsinbar, G., Aw, T. Y., Wong, S., Venkataraman, S., Lim, F. W. I., Vandepapelière, P., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c06350 · Cited by 33
Essential Attributes of Clear Aligner Therapy in terms of Appliance Configuration, Hygiene, and Pain Levels during the Pandemic: A Brief Review
Marya, A., Venugopal, A., Vaiid, N., Alam, M. K., & Karobari, M. I. (2020) · Pain Research and Management · doi:10.1155/2020/6677929 · Cited by 33
COVID-19: vaccines, efficacy and effects on variants
Rudan, I., Adeloye, D., & Sheikh, A. (2022) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000868 · Cited by 34
Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion
Ren, W., Ju, X., Gong, M., Lan, J., Yu, Y., Long, Q., Kenney, D., O’Connell, A. K., Zhang, Y. L., Zhong, J., et al. (2022) · mBio · doi:10.1128/mbio.00099-22 · Cited by 40
The development of DNA vaccines against SARS-CoV-2
Khalid, K., & Poh, C. L. (2023) · Advances in Medical Sciences · doi:10.1016/j.advms.2023.05.003 · Cited by 37
Vaccination Is the Only Acceptable Path to Herd Immunity
Rasmussen, A. L. (2020) · Med · doi:10.1016/j.medj.2020.12.004 · Cited by 41
Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates
Mukhopadhyay, L., Yadav, P. D., Gupta, N., Mohandas, S., Patil, D. Y., Shete-Aich, A., Panda, S., & Bhargava, B. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_4431_20 · Cited by 35
Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
Zhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 35
Structural and Dynamical Differences in the Spike Protein RBD in the SARS-CoV-2 Variants B.1.1.7 and B.1.351
Bhattarai, N., Baral, P., Gerstman, B. S., & Chapagain, P. P. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c01626 · Cited by 32
Synthetic SARS-CoV-2 Spike-Based DNA Vaccine Elicits Robust and Long-Lasting Th1 Humoral and Cellular Immunity in Mice
Alamri, S. S., Alluhaybi, K. A., Alhabbab, R. Y., Basabrain, M. A., Algaissi, A. A., Almahboub, S. A., Alfaleh, M. A., Abujamel, T. S., Abdulaal, W. H., ElAssouli, M.-Z. M., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.727455 · Cited by 33
Evaluation of adverse effects with COVID-19 vaccination in Pakistan
Abbas, D. S., Abbas, B., Amir, S., & Wajahat, M. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.7.4522 · Cited by 34
Single domain shark VNAR antibodies neutralize SARS‐CoV‐2 infection in vitro
Gauhar, A., Privezentzev, C. V., Demydchuk, M., Gerlza, T., Rieger, J., Kungl, A. J., Walsh, F. S., Rutkowski, J. L., & Stocki, P. (2021) · The FASEB Journal · doi:10.1096/fj.202100986rr · Cited by 30
Production and secretion of functional SARS-CoV-2 spike protein in Chlamydomonas reinhardtii
Kiefer, A. M., Niemeyer, J., Probst, A., Erkel, G., & Schroda, M. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2022.988870 · Cited by 37
Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
He, W., Yuan, M., Callaghan, S., Musharrafieh, R. G., Song, G., Silva, M., Beutler, N., Lee, W.-H., Yong, P., Torres, J. L., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl9605 · Cited by 32
Current state of, prospects for, and obstacles to mRNA vaccine development
Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 35
Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies
Faraji, N., Zeinali, T., Joukar, F., Aleali, M. S., Eslami, N., Shenagari, M., & Mansour‐Ghanaei, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30208 · Cited by 32
Biomaterials-based formulations and surfaces to combat viral infectious diseases
Kumari, S., & Chatterjee, K. (2021) · APL Bioengineering · doi:10.1063/5.0029486 · Cited by 32
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19
Malherbe, D. C., Kurup, D., Wirblich, C., Ronk, A. J., Mire, C. E., Kuzmina, N. A., Shaik, N. F., Periasamy, S., Hyde, M. A., Williams, J. M., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00352-1 · Cited by 31
An in-depth in silico and immunoinformatics approach for designing a potential multi-epitope construct for the effective development of vaccine to combat against SARS-CoV-2 encompassing variants of concern and interest
Saba, A. A., Adiba, M., Saha, P., Hosen, M. I., Chakraborty, S., & Nabi, A. N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104703 · Cited by 33
The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein
Girt, G. C., Lakshminarayanan, A., Huo, J., Dormon, J., Norman, C. S., Afrough, B., Harding, A. C., James, W., Owens, R. J., & Naismith, J. H. (2021) · Royal Society Open Science · doi:10.1098/rsos.211016 · Cited by 33
Inhalable mRNA vaccines for respiratory diseases: a roadmap
Roh, E. H., Fromen, C. A., & Sullivan, M. O. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.10.017 · Cited by 32
Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial
Thuluva, S., Paradkar, V. M., Gunneri, S., Yerroju, V., Mogulla, R. R., Suneetha, P. V., Turaga, K., Kyasani, M., Manoharan, S. K., Adabala, S., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2203632 · Cited by 32

Authors: Krammer, F.
Affiliations: Icahn School of Medicine at Mount Sinai (US)
Corresponding author: Krammer, Florian
ORCID: Krammer, Florian
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2020-09-23
Volume: 586
Issue: 7830
Pages: 516-527
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-020-2798-3
OpenAlex: W3087924281
Cited by: 2,098
References: 101
Citations by year: 2026: 91 · 2025: 147 · 2024: 173 · 2023: 287 · 2022: 538 · 2021: 747 · 2020: 112
FWCI: 19.97
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by
www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Zenodo (CERN European Organization for Nuclear Research) (cc-by)
Funders: JPB Foundation (2020-215611, HHSN272201400008C, 75N93019C00051)
Open Philanthropy Project (#2020-215611, 75N93019C00051, HHSN272201400008C)
National Institute of Allergy and Infectious Diseases (HHSN272201400008C), 75N93019C00051, 2020-215611, HHSN272201800048C)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: SARS-CoV-2, COVID-19 vaccines, vaccine development, vaccine candidate, clinical trials, animal studies, vaccine safety, vaccine efficacy, COVID-19 pandemic
MeSH terms: Drug Development, COVID-19, COVID-19 Vaccines, Animals, Clinical Trials as Topic, Drug Industry, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Immunity, Mucosal, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

SARS-CoV-2 vaccines in development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks